Phase I Study of Cisplatin And ZD1839 (IRESSA) [gefitinib] in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck.
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Cisplatin; Gefitinib
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 14 May 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 23 Dec 2005 New trial record.